Cancer carbohydrates are now a key target for the development of effective and safe cancer vaccines. To investigate the most effective anti-cancer strategies, CD BioGlyco has focused on the development of tumor-associated carbohydrate antigens (TACAs)-based cancer vaccines for many years. We are confident to be your scientific assistant in the field of vaccine development.
Cancer cells can be distinguished from normal cells by displaying abnormal types and levels of carbohydrate structures on the surface of cancer cells. These carbohydrate structures are known as TACA, which are considered promising targets for the design of anti-cancer vaccines. This vaccine can be recognized by the immune system and produce an immune response. Antibodies produced against carbohydrate antigens participate in the inactivation of carbohydrate-modified cancer cells by slowing tumor cell growth and inducing apoptosis.
However, most carbohydrate antigens are T-cell-independent and produce weak immune responses. In addition, it is easy to induce immune tolerance and immunosuppression due to the endogenous nature of naturally occurring TACAs, which increases the challenge of their application in cancer vaccines. To enhance immunogenicity, researchers usually couple them with carrier proteins or chemically modify them. Currently, multiple heterogeneous populations of TACA expressed in tumors may represent the most effective anticancer strategy.
Fig.1 Immunological response to carbohydrate antigens. (a). Carbohydrates bind B-cell receptors, initiating a weak T-cell-independent response. (b). Induction of T-cell-dependent response by conjugated vaccines. (Feng, et al., 2016)
To improve the immune response and address challenges related to immune tolerance and immunosuppression, CD BioGlyco has dedicated significant efforts towards Carbohydrate-based Vaccine Development, particularly those targeting TACA for cancer research. With our advanced Glyco™ Vaccine Development Platform, we are confident in serving as your scientific partner in the field of vaccine research and development.
Over the past few decades, CD BioGlyco has become a leading provider of exceptional and high-quality services in tumor-associated glycopeptide antigens production. We strive to deliver reliable and efficient solutions that contribute to advancing discoveries in the field of tumor-associated glycopeptide antigens.
At CD BioGlyco, we understand the critical role of glycolipid antigens in research and clinical applications. Hence, our dedication lies in delivering unparalleled glycolipid antigen production services that are trustworthy and resilient for our clients.
With our cutting-edge platform, CD BioGlyco provides a streamlined pathway for your research and development related to the production of tumor-associated ganglioside antigens.
With a strong commitment to scientific excellence and client satisfaction, we continue to drive innovation in tumor-associated globo antigen production services worldwide. The antigens incorporated in our service are listed below.
Our team of experienced scientists and technicians utilizes cutting-edge technologies and state-of-the-art facilities to ensure the efficient synthesis and purification of these complex antigens.
As a leading global provider of glycolipid antigen production services, CD BioGlyco is dedicated to delivering high-quality and reliable solutions for the production of tumor-associated neo-lactone series antigens. The antigens included in our tumor-associated neolacto-series antigen production service are as follows:
The development of a tumor-associated carbohydrate vaccine typically involves the following steps: Firstly, researchers need to identify carbohydrate antigens associated with the target cancer and purify and prepare them. Secondly, researchers need to combine these carbohydrate antigens with appropriate adjuvants to activate the immune system and generate an immune response. Ultimately, researchers must undertake clinical trials to assess the safety and effectiveness of the vaccine.
No tumor-associated carbohydrate vaccines have been approved for formal clinical use. However, some vaccines have entered clinical trials and have shown some potential.
With advanced experimental platforms and professional knowledge in the field of chemistry and biology, CD BioGlyco assists clients in the development of promising carbohydrate antigens to ensure that they reach the maximum and desired immune response level. Please feel free to contact us if you are interested in our services.
Reference
